BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application for the use of its Survivin antagonist. The Company will open a Phase I study evaluating safety of the Survivin antagonist during the first quarter of 2009.
